1. Home
  2. IRWD vs TRDA Comparison

IRWD vs TRDA Comparison

Compare IRWD & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IRWD
  • TRDA
  • Stock Information
  • Founded
  • IRWD 1998
  • TRDA 2016
  • Country
  • IRWD United States
  • TRDA United States
  • Employees
  • IRWD N/A
  • TRDA N/A
  • Industry
  • IRWD Biotechnology: Pharmaceutical Preparations
  • TRDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • IRWD Health Care
  • TRDA Health Care
  • Exchange
  • IRWD Nasdaq
  • TRDA Nasdaq
  • Market Cap
  • IRWD 716.9M
  • TRDA 609.7M
  • IPO Year
  • IRWD 2010
  • TRDA 2021
  • Fundamental
  • Price
  • IRWD $4.44
  • TRDA $17.63
  • Analyst Decision
  • IRWD Buy
  • TRDA Strong Buy
  • Analyst Count
  • IRWD 4
  • TRDA 3
  • Target Price
  • IRWD $12.00
  • TRDA $21.67
  • AVG Volume (30 Days)
  • IRWD 1.5M
  • TRDA 166.9K
  • Earning Date
  • IRWD 11-07-2024
  • TRDA 11-05-2024
  • Dividend Yield
  • IRWD N/A
  • TRDA N/A
  • EPS Growth
  • IRWD N/A
  • TRDA N/A
  • EPS
  • IRWD 0.06
  • TRDA 3.04
  • Revenue
  • IRWD $400,565,000.00
  • TRDA $239,397,000.00
  • Revenue This Year
  • IRWD N/A
  • TRDA $39.06
  • Revenue Next Year
  • IRWD $2.80
  • TRDA N/A
  • P/E Ratio
  • IRWD $78.45
  • TRDA $5.76
  • Revenue Growth
  • IRWD N/A
  • TRDA 451.22
  • 52 Week Low
  • IRWD $3.79
  • TRDA $10.75
  • 52 Week High
  • IRWD $15.70
  • TRDA $18.17
  • Technical
  • Relative Strength Index (RSI)
  • IRWD 52.71
  • TRDA 61.79
  • Support Level
  • IRWD $4.06
  • TRDA $15.65
  • Resistance Level
  • IRWD $4.39
  • TRDA $18.01
  • Average True Range (ATR)
  • IRWD 0.24
  • TRDA 0.75
  • MACD
  • IRWD 0.07
  • TRDA 0.17
  • Stochastic Oscillator
  • IRWD 82.35
  • TRDA 86.52

About IRWD Ironwood Pharmaceuticals Inc.

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient delivery of a wide range of therapeutics into a variety of organs and tissues, resulting in an improved therapeutic index. Its pipeline includes solutions for Neuromuscular Disease, Beyond Neuromuscular, and Platform Expansion.

Share on Social Networks: